Who We Are

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.

Our Pipeline

Our lead product, OC-01, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01’s novel mechanism of action is designed to reestablish tear film homeostasis by activating natural tear film production.

Latest News

12/29/2020

Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

12/18/2020

Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease